bpc-157 human evidence randomized clinical trial 2024 controlled 🙋🏻‍♂️ Is the lack of Regeneration or Risk? A Narrative

at China Pharmaceutical University and Nanjing First Hospital: oral Dihexa restored spatial learning and memory in the APP/PS1 transgenic mouse model of Alzheimers disease via the PI3K/AKT signaling pathway, reduced neuroinflammation, and preserved hippocampal synaptophysin expression (Sun et al., Brain Sciences 2021)

The regulatory gap is the headline

During the transition process, the following aspects should be considered among others: Role changes of patients, parents and caregivers, active involvement of stakeholders in the planning and decision-making processes, comprehensive knowledge about the illness and its course

Defense Dihexa has been studied for pathways involved in protecting neurons from oxidative stress, inflammation, and age-related cognitive decline